Winning the Championship！Nanolattix T320 Innovation Project Wins First Prize in Provincial Round of the 14th China Innovation and Entrepreneurship Competition
Release time:
2025-09-01
On August 15, 2025, the award ceremony of the Shanxi Division of the 14th China Innovation and Entrepreneurship Competition was grandly held in Luliang. Nanolattix “ADC Antibody-Drug Conjugate Anti-Cancer New Drug and Companion Diagnostics” project won the first prize in the finals for its remarkable innovation and application prospects. It will now compete in the national round as an outstanding innovation and entrepreneurship project from Shanxi Province!
Nanolattix T320-ADC antibody-drug conjugate anti-cancer new drug has demonstrated breakthrough potential in treating various malignant tumors, such as cervical cancer, pancreatic cancer, and ovarian cancer. It is currently undergoing multi-center clinical trials and is expected to provide more precise and effective treatment options for cancer patients.
This award authoritatively recognizes Nanolattix innovative capabilities and core technological strengths, highlighting its leading position in the biomedicine field in Shanxi Province, particularly in the development of innovative anti-cancer therapies.
Under the theme “Gathering for Innovation, Advancing Together,” this competition brought together nearly 500 outstanding enterprises from across the province. The projects covered multiple cutting-edge fields, including biomedicine, new-generation information technology, and high-end equipment manufacturing. At the event, Nanolattix deepened exchanges with upstream and downstream partners in the industrial chain, jointly exploring a new future for high-quality enterprise development.
Taking this award as an opportunity, Nanolattix will continue to enhance its scientific research capabilities, deepen its engagement in the biomedicine field, and contribute further to the industrial transformation and upgrading of Shanxi Province.
Tag:
Previous Page
recommend News
Share
